会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • TRANSDERMAL DELIVERY SYSTEMS
    • WO2006047362A2
    • 2006-05-04
    • PCT/US2005038086
    • 2005-10-21
    • DURECT CORPYUM SU IITHEEUWES FELIX
    • YUM SU IITHEEUWES FELIX
    • A61K9/70A61K31/445
    • A61K9/703A61F2013/0296A61K9/7053A61K9/7061A61K9/7084A61K31/445A61K31/4535A61M35/00
    • Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.
    • 提供了通过皮肤施用舒芬太尼的透皮递送系统。 该系统含有足够量的舒芬太尼,以在应用于受试者时诱导和维持恒定的止痛状态。 该系统的特征在于具有一个或多个特征,包括对来自系统的舒芬太尼通量的高度剂量率控制,来自系统通过皮肤的高舒芬太尼净通量,缺乏渗透促进剂,展示粘合剂构件 优越的剪切时间,来自系统的舒芬太尼的净通量的低变化系数,高的递送效率以及来自系统的舒芬太尼的基本恒定的稳态净通量。 还提供了使用透皮递送系统施用足够量的舒芬太尼以在施用于受试者时长时间诱导和维持镇痛的方法。
    • 2. 发明申请
    • EXPANDABLE BORE INJECTION NEEDLE
    • 可膨胀的注射针
    • WO2004067062A3
    • 2006-05-04
    • PCT/US2004002447
    • 2004-01-28
    • DURECT CORP
    • GILLIS EDWARD MFILICE JAMES ABROWN JIMRAMPERSAUD CHARLESPOUTIATINE ANDREWARGONZA DANNY
    • A61B17/34A61M20060101A61M5/178
    • A61B17/3468A61B17/3439
    • The present invention is a trocar/cannula assembly that is capable of delivering large-diameter objects/fluids into a body cavity interior, while minimizing the puncture footprint left after insertion. Generally, the invention could be a composite needle (12) having a composite wall (18) forming a trocar shaft (18) with at least two rigid elements (20), and flexible material (26) therebetween, which together at least partially define a trocar bore having a diameter, and a puncture tip (30). Together these elements enable the composite wall to flex outward so as to increase the diameter of the trocar bore. Additionally, the present invention could also be described as an expandable bore trocar/cannula that is made up of an expandable cannula body (40) having an interior channel that is capable of flexing radially outward, and a trocar tip associated with the cannula body to facilitate the insertion of the trocar/cannula into a patient.
    • 本发明是一种套管针/套管组件,其能够将大直径物体/流体输送到体腔内部,同时最小化插入后留下的穿刺足迹。 通常,本发明可以是具有形成具有至少两个刚性元件(20)的套管针轴(18)的复合壁(18)和其间的柔性材料(26)的复合针(12),其一起至少部分地限定 具有直径的套管针孔和穿刺尖端(30)。 这些元件一起使得复合壁向外弯曲,从而增加套管针孔的直径。 另外,本发明还可以被描述为由可扩张的套管主体(40)构成的可扩展的套管针/套管,其具有能够径向向外弯曲的内部通道,以及与插管主体相关联的套针针头 有助于套管针/套管插入患者体内。
    • 7. 发明申请
    • CONTROLLED DELIVERY SYSTEM
    • 控制输送系统
    • WO2006033948A2
    • 2006-03-30
    • PCT/US2005032863
    • 2005-09-15
    • DURECT CORPVERITY NEIL A
    • VERITY NEIL A
    • A61K47/26A61K9/08A61K31/445B60C27/10
    • A61K31/445A61K9/0014A61K9/0019A61K9/0024A61K9/08A61K9/107A61K9/7015A61K45/06A61K47/22A61K47/26
    • The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.
    • 本发明涉及含有非聚合物载体材料和麻醉剂的新型麻醉剂组合物,其中组合物适于提供持续的局部麻醉而没有初始爆发并具有约24小时或更长时间的持续时间。 还提供了包括第一麻醉剂和第二麻醉剂的某些组合物。 在这种组合物中,第二麻醉剂是用于第一麻醉剂的溶剂,并且在给予受试者时提供初始麻醉效果。 非聚合物载体可以任选地是高粘度液体载体材料,例如合适的糖酯。 组合物还可以包括一种或多种另外的成分,包括活性和非活性材料。 还提供了使用本发明组合物在受试者的部位产生持续麻醉效果的方法。
    • 8. 发明申请
    • IMPLANT ANCHOR AND METHODS OF USE
    • 植入锚和使用方法
    • WO2004049919A3
    • 2004-09-02
    • PCT/US0338549
    • 2003-12-04
    • DURECT CORPPOUTIATINE ANDREW I
    • POUTIATINE ANDREW I
    • A61B20060101A61F2/06A61M25/04
    • A61M25/04A61F2/848
    • An implant anchor (26) that holds an implant (18) in place by fibrotic encapsulation or inclusion of surrounding tissue into the anchor. The apparatus of the invention comprises an anchor (26) configured to couple to an implant (18) and which has at least one fibrous surface or portion capable of becoming fibrously encapsulated or included by surrounding tissue. The methods of the invention comprise providing an anchor (26) having at least one porous surface or portion thereon, attaching the anchor (26) to an implant (18), positioning the implant (18) and attached anchor (26) in a patient incision, and fibrotically encapsulating the anchor (26).
    • 通过纤维化包封或将周围组织包含在锚中而将植入物(18)保持在适当位置的植入物锚固件(26)。 本发明的装置包括构造成联接到植入物(18)并且具有至少一个纤维表面或部分能够被纤维状包封或由周围组织包围的锚定件(26)。 本发明的方法包括提供在其上具有至少一个多孔表面或部分的锚固件(26),将锚固件(26)附接到植入物(18),将植入物(18)和附着的锚固件(26)定位在患者体内 切口,以及纤维封装锚(26)。